2United Kingdom Prospective Diabetes Study Group. Tight bloom pressure control and risk of macrovascular and microvascular complications in type 2 diabetes(UKPD:38) [J]. BMJ,1998, 317(7160):703-713.
4Gomis R,Jones NP,Vallance SE,et al.Low-dose rosiglitazone enhance glycemic control when combined with sulphonylureas in type 2 diabetes[].Diabetologia.1999
5Kreider M,Miller E,Patel J.Rosiglitazone is safe and well tolerated as monotherapy or combination therapy in patients with type 2 diabetes mellitus (T2DM)[].Diabetes.1999
6Reiusset J,Auwerk J,Vidal H.Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone ( BRL 49563 ) in human adipocytes[].Biochemical and Biophysical Research Communications.1999
7Salzman A.Rosiglitazone is not associated with hepatotoxicity[].Diabetologia.1999
8Lebovitz HE,Patel J,Dole J,et al.Rosiglitazone (BRL 49653)monotherapy has significant glucose effect in type 2 diabetic patients[].Diabetologia.1998
9Fonseca V,Biswas N,Salzmann A.Rosiglitazone in combination with metformin effectively reduces hyperglycemia in patients with type 2 diabetes[].Diabetologia.1999
10Tabona MV,Weill S,Patwardhan R.Rosiglitazone given once or twice daily is effective first-line treatment for type 2 diabetes mellitus[].Diabetologia.1999
